CIK 0001425205 · Accelerated filer
IOVANCE BIOTHERAPEUTICS, INC.
Sign in to watch- Ticker
- IOVA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 753254381
- Phone
- 6502607120
- Business address
- 825 INDUSTRIAL ROAD, 4TH FLOOR, SAN CARLOS, CA, 94070
- Former names
- Lion Biotechnologies, Inc., Genesis Biopharma, Inc, FREIGHT MANAGEMENT CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-03 | Bellemin Jean-Marc Chief Financial Officer | Shares withheld for taxes | −31,734 | $4.04 | $128K | 56,204 |
| 2025-03-03 | Bellemin Jean-Marc Chief Financial Officer | Option exercise · Restricted Stock Units | −58,590 | 70,317 | ||
| 2025-03-03 | BILINSKY IGOR Chief Operating Officer | Option exercise | +62,106 | 120,880 | ||
| 2025-03-03 | BILINSKY IGOR Chief Operating Officer | Shares withheld for taxes | −33,302 | $4.04 | $135K | 87,578 |
| 2025-03-03 | BILINSKY IGOR Chief Operating Officer | Option exercise · Restricted Stock Units | −3,516 | 14,065 | ||
| 2025-03-03 | BILINSKY IGOR Chief Operating Officer | Option exercise · Restricted Stock Units | −58,590 | 70,317 | ||
| 2025-03-03 | Vogt Frederick G Interim CEO & General Counsel | Option exercise | +223,943 | 445,059 | ||
| 2025-03-03 | Vogt Frederick G Interim CEO & General Counsel | Shares withheld for taxes | −95,413 | $4.04 | $385K | 349,646 |
| 2025-03-03 | Vogt Frederick G Interim CEO & General Counsel | Option exercise · Restricted Stock Units | −10,418 | 41,669 | ||
| 2025-03-03 | Vogt Frederick G Interim CEO & General Counsel | Option exercise · Restricted Stock Units | −213,525 | 333,350 | ||
| 2025-03-03 | Puri Raj K. Chief Regulatory Officer | Option exercise | +59,999 | 215,411 | ||
| 2025-03-03 | Puri Raj K. Chief Regulatory Officer | Shares withheld for taxes | −19,984 | $4.04 | $81K | 195,427 |
| 2025-03-03 | Puri Raj K. Chief Regulatory Officer | Option exercise · Restricted Stock Units | −59,999 | 43,756 | ||
| 2025-03-03 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Option exercise | +62,497 | 126,383 | ||
| 2025-03-03 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Shares withheld for taxes | −33,470 | $4.04 | $135K | 92,913 |
| 2025-03-03 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Option exercise · Restricted Stock Units | −3,907 | 15,626 | ||
| 2025-03-03 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Option exercise · Restricted Stock Units | −58,590 | 70,317 | ||
| 2025-02-10 | Kirby Daniel Gordon Chief Commercial Officer | Grant or award · Stock Options (Right to Buy) | +35,000 | 35,000 | ||
| 2025-02-10 | Kirby Daniel Gordon Chief Commercial Officer | Grant or award · Restricted Stock Units | +120,000 | 120,000 | ||
| 2025-02-10 | Kirby Daniel Gordon Chief Commercial Officer | Grant or award · Performance Stock Units | +150,000 | 150,000 |
Page 10 of 14 · 280 trades